ART-123
Product
Veloxis Pharmaceuticals, Inc.
Total Payments
$366,920
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $366,920 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $366,920 | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Assess Safety and Tolerability of ART-123 and FOLFOX Bevacizumab in Metastatic Colorectal Cancer Patients | Veloxis Pharmaceuticals, Inc. | $366,920 | 0 |
Top Doctors Receiving Payments for ART-123
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bethesda, MD | $366,920 | 11 |
Ad
Manufacturing Companies
- Veloxis Pharmaceuticals, Inc. $366,920
Product Information
- Type Product
- Total Payments $366,920
- Total Doctors 0
- Transactions 11
About ART-123
ART-123 is a product associated with $366,920 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Veloxis Pharmaceuticals, Inc..
Payment data is available from 2022 to 2022. In 2022, $366,920 was paid across 11 transactions to 0 doctors.
The most common payment nature for ART-123 is "Unspecified" ($366,920, 100.0% of total).
ART-123 is associated with 1 research study, including "Assess Safety and Tolerability of ART-123 and FOLFOX Bevacizumab in Metastatic Colorectal Cancer Patients" ($366,920).